-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Chinese University announced on the 4th that Mo Shujin, a global lung cancer authority and head of the Department of Oncology at
Chinese University (CUHC) School of Medicine, has been hailed as a "Giant of Oncology" by OncLive, an internationally renowned multimedia resource platform for oncology, praising his outstanding leadership and contribution to lung cancer research and treatment, which has revolutionization in cancer treatment worldwide.
was one of the first Asian experts to receive this international award, and the first award-winning scholar from outside European and American institutions.
According to CUHK, Mo Shujin focused on biomarker and molecular target therapy and immunotherapy related to lung cancer, and his research published in 2009 confirmed that lung cancer patients with EGFR gene mutations had better results than chemotherapy, and formally established target therapy as a first-line treatment for EGFR gene variant lung cancer.
, Mo Shujin in 2014 confirmed that target therapy is more effective than traditional chemotherapy to treat APK-positive lung cancer patients with advanced lung cancer. Currently, patients with both types of cancer generally have a survival period of more than three to five years. In the past, the only treatment for advanced lung cancer was chemotherapy, which had an average survival of only about one year.
said it was a great honor to be honored to be the "2020 Giant of Oncology" with the world's leading oncologist authorities. He thanked every researcher who had worked together over the years for overcoming difficulties step by step, improving lung cancer treatment and endlessly declaring war on lung cancer.
"OncLive" Award was founded by OncLive, a well-known multimedia resource platform for oncology in the United States. This year, more than 800 cancer specialists from around the world were nominated, and 15 of the world's top cancer specialists were selected by a
panel of more than 120 internationally renowned oncologists, doctors and researchers.
